Photodynamic therapy-induced apoptosis in epidermoid carcinoma cells. Reactive oxygen species and mitochondrial inner membrane permeabilization.
Photodynamic therapy (PDT), a novel and promising cancer treatment that employs a combination of a photosensitizing chemical and visible light, induces apoptosis in human epidermoid carcinoma A431 cells. However, the precise mechanism of PDT-induced apoptosis is not well characterized. To dissect the pathways of PDT-induced apoptosis, we investigated the involvement of mitochondrial damage by examining a second generation photosensitizer, the silicon phthalocyanine 4 (Pc 4). By using laser-scanning confocal microscopy, we found that Pc 4 localized to cytosolic membranes primarily, but not exclusively, in mitochondria. Formation of mitochondrial reactive oxygen species (ROS) was detected within minutes when cells were exposed to Pc 4 and 670-675 nm light. This was followed by mitochondrial inner membrane permeabilization, depolarization and swelling, cytochrome c release, and apoptotic death. Desferrioxamine prevented mitochondrial ROS production and the events thereafter. Cyclosporin A plus trifluoperazine, blockers of the mitochondrial permeability transition, inhibited mitochondrial inner membrane permeabilization and depolarization without affecting mitochondrial ROS generation. These data indicate that the mitochondrial ROS are critical in initiating mitochondrial inner membrane permeabilization, which leads to mitochondrial swelling, cytochrome c release to the cytosol, and apoptotic death during PDT with Pc 4.
Lam
M
M
Department of Anatomy, Case Western Reserve University School of Medicine, 10900 Euclid Ave., Cleveland, OH 44106, USA.
Oleinick
N L
NL
Nieminen
A L
AL
D017209:Apoptosis; D015153:Blotting, Western; D002277:Carcinoma / Q000378:metabolism*; D053148:Caspase 3; D061945:Caspase Inhibitors; D002462:Cell Membrane / Q000378:metabolism; D002470:Cell Survival; D003574:Cytochrome c Group / Q000378:metabolism; D003600:Cytosol / Q000378:metabolism; D003676:Deferoxamine / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D004307:Dose-Response Relationship, Radiation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D007211:Indoles / Q000378:metabolism*; D007425:Intracellular Membranes / Q000378:metabolism*; D007502:Iron Chelating Agents / Q000494:pharmacology; D008027:Light; D018613:Microscopy, Confocal; D008928:Mitochondria / Q000378:metabolism*; D008954:Models, Biological; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000494:pharmacology; D017382:Reactive Oxygen Species; D012878:Skin Neoplasms / Q000378:metabolism*; D013997:Time Factors; D014268:Trifluoperazine / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D061945:Caspase Inhibitors; D003574:Cytochrome c Group; D018492:Dopamine Antagonists; D004791:Enzyme Inhibitors; D007211:Indoles; D007502:Iron Chelating Agents; D017319:Photosensitizing Agents; D017382:Reactive Oxygen Species; C107448:phthalocyanine Pc 4; D014268:Trifluoperazine; C505407:CASP3 protein, human; D053148:Caspase 3; D003676:Deferoxamine